Superinvestors / Hillman Capital Management
Mark Hillman
Hillman Capital Management
Intrinsic-value driven value
This quarter
Positions held steady are not reported as moves, so they are absent from these counts.
Portfolio
By weight · every resolvable issuer links to its company page · tags are this quarter's reported move
| Ticker | Issuer | % of portfolio | Reported price | Value | Shares |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORPDECREASED -17.8% | 4.15% | $103.45 | $5.74M | 55.5K |
| BIIB | BIOGEN INCDECREASED -18.8% | 3.75% | $216.06 | $5.18M | 24.0K |
| DD | DUPONT DE NEMOURS INC· COMMON STOCK *A*NEW | 3.71% | $135.64 | $5.12M | 37.7K |
| WBD | WARNER BROS DISCOVERY INC· COM SER ADECREASED -3.2% | 3.67% | $26.66 | $5.07M | 190.0K |
| BAX | BAXTER INTL INCDECREASED -4.6% | 3.64% | $21.32 | $5.03M | 236.0K |
| IFF | INTERNATIONAL FLAVORS&FRAGRADECREASED -13.6% | 3.61% | $79.22 | $4.98M | 62.9K |
| GSK | GSK PLC· SPONSORED ADRDECREASED -5.2% | 3.51% | $52.42 | $4.84M | 92.4K |
| KMX | CARMAX INCDECREASED -16.3% | 3.50% | $52.89 | $4.83M | 91.4K |
| BA | BOEING CODECREASED -3.4% | 3.38% | $216.47 | $4.67M | 21.6K |
| ZBH | ZIMMER BIOMET HOLDINGS INCDECREASED -3.2% | 3.36% | $86.09 | $4.64M | 53.9K |
Reported price is this manager's own reported value divided by its own reported shares at 2026-06-30 — not a live quote, and not what they paid. 13F reports no cost basis.
The top 10 positions are 36.3% of the reported portfolio, across 54 positions.
Values are as disclosed on this manager’s own 13F for its own quarter. 13F covers US-listed long equity only, so this is not the manager’s entire portfolio.
See more of Mark Hillman's portfolio
More of Mark Hillman's reported positions with their weights, and what they bought, sold and trimmed last quarter rather than the largest few — free with an account, no card required.
Sign in free